

09-22-03...

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → ☐ +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/611,459
		Filing Date	July 1, 2003
		First Named Inventor	Keith Robert Hildebrand
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Total Number of Pages in This Submission		Attorney Docket Number	11738.00161

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO/SB/08A References Return receipt postcard
Remarks The Commissioner is authorized to charge any fees in connection with this correspondence to Deposit Account No. 19-0733. A duplicate of this sheet is enclosed.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	William J. Allen
Signature	<i>William J. Allen</i> 51,393
Date	September 18, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <input type="text"/>		
Typed or printed name		
Signature		Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No.: 11738.00161)



the Application of:)	
)	
Keith Robert Hildebrand)	
)	Examiner: unassigned
Serial No.: 10/611,459)	
)	
Filed: July 1, 2003)	Group Art Unit: unassigned
)	
For: A method for treating severe tinnitus)	

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Alexandria, VA 22313-1450

Pursuant to 37 C.F.R. § 1.97 and 1.98, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. § 1.56. Copies of the references cited below are enclosed. The references are also listed on the enclosed and completed Form PTO/SB/08A.

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(b) within three months of this application's filing date or before the mailing date of a first Office Action on the merits. Accordingly, there is no fee due for filing this Information Disclosure Statement.

Under 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Under 37 C.F.R. § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the cited reference is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

REFERENCES

U.S. Patents:

1. Howard, III, U.S. Patent No. 5,496,369, issued on March 5, 1996
2. Howard, III et al., U.S. Patent No. 5,676,655, issued on October 14, 1997
3. Howard, III et al., U.S. Patent No. 5,713,847, issued on February 3, 1998

Prior Art:

1. LEWIS, J.E., S.D.G. STEPHENS, ET AL., "Tinnitus and suicide." July 7, 1993, pgs. 50-54, vol. 19, Clin Otolaryngol.
2. MCFADDEN, D., Tinnitus: Facts, Theories, and Treatments, 1982, pgs. 1-9, National Academy Press, Washington D.C.
3. SATALOFF, J., R.T. SATALOFF, ET AL., "Tinnitus and vertigo in healthy senior citizens without a history of noise exposure." March 1987, pgs. 87-89, vol. 2, Thieme Medical Publishers, Inc., New York, NY.
4. AXELSSON, A. and A. RINGDAHL, "Tinnitus-a study of its prevalence and characteristics.", 1989, pgs. 53-56, vol. 23, British Journal of Audiology
5. COLES, R. R. A., THOMPSON, ET AL., "Intra-tympanic injections in the treatment of tinnitus.", 1992, pgs. 240-242, vol. 17, Clin Otolaryngol.
6. DOBIE, R.A., "A review of randomized clinical trials in tinnitus." , The Laryngoscope, August 1999, pgs. 1202-1211, Lippincott Williams & Wilkins, Inc., Philadelphia.
7. LOCKWOOD, A.H., R.J. SALVI, ET AL., "The functional neuroanatomy of tinnitus: Evidence for limbic system links and neural plasticity.", January, 1998, Neurology, pgs. 114-120, vol. 50, American Academy of Neurology.
8. MOLLER, A.R., "Symptoms and signs caused by neural plasticity." Neurological Research, September, 2001, pgs. 565-572, vol. 23, Forefront Publishing Group.
9. DEN HARTIGH, J., C. G. J. M. HILDERS, ET AL., "Tinnitus suppression by intravenous lidocaine in relation to its plasma concentration." Clinical Pharmacology & Therapeutics, October 1993, pgs 415-420, vol. 54 no. 4, Mosby- Year Book, Inc.
10. OCHI, K. and J.J. EGGERMONT, "Effects of salicylate on neural activity in cat primary auditory cortex." Hearing Research, 1996, pgs 63-76, vol. 95, Elsevier Science B.V.

11. CASPARY, D.M., J. C. MILBRANDT, ET AL., "Central Auditory Aging: GABA Changes in the Inferior Colliculus." *Experimental Gerontology*, 1995, pgs. 349-360, vol. 30 nos. 3/4, Elsevier Science Ltd. , USA.
12. MCGEER, E. G. and P. L. MCGEER, "AGE CHANGES IN THE HUMAN FOR SOME ENZYMES ASSOCIATED WITH METABOLISM OF THE CATECHOLAMINES, GABA AND ACETYLCHOLINE." *Neurobiology of Aging*, 1975, pgs. 287-305, Plenum Press, New York.
13. RAZA, A., J. C. MILBRANDT, ET AL., "Age-Related Changes in Brainstem Auditory Neurotransmitters: Measures of GABA and Acetylcholine Function." *Hearing Research*, 1994, pgs. 221-230, vol. 77, Elsevier Science B. V.
14. ARAKI, T., H. KATO, ET AL., "Selective changes of neurotransmitter receptors in middle-aged gerbil brain." *Neurochem. Int.*, 1993, pgs. 541-548, vol. 23 no. 6, Pergamon Press Ltd.
15. MILDBRANDT, J. C., R. L. ALBIN, ET AL., "Age-Related Decrease in GABA_B Receptor Binding in the Fischer 344 Rat Inferior Colliculus." *Neurobiology of Aging*, 1994, pgs. 699-703, vol. 15 no. 6, Elsevier Science Ltd., USA.
16. MOLLER, A. R., M. B. MOLLER, ET AL., "Some Forms of Tinnitus May Involve the Extralemniscal Auditory Pathway." *Laryngoscope*, October 1992, pgs. 1165-1171.
17. SZCZRPANIAK, W. S. and A. R. MOLLER, "EFFECTS OF L-BACLOFEN AND D-BACHLOFEN ON THE AUDITORY SYSTEM: A STUDY OF CLICK-EVOKED POTENTIALS FROM THE INFERIOR COLLICULUS IN THE RAT." *Ann Otol Rhinol Laryngol*, 1995, pgs. 399-404.
18. SZCZEPANIAK, W. S. and A.R. MOLLER, "Effects of (-) baclofen, clonazepam, and diazepam on tone exposure-induced hyperexcitability of the inferior colliculus in the rat: possible therapeutic implications for pharmacological management of tinnitus and hyperacusis." *Hearing Research*, 1996, pgs. 46-53, Elsevier Science B.V.
19. LEES, A. J., C. R. CLARKE, ET AL., "HALLUCINATIONS AFTER WITHDRAWAL OF BACLOFEN." *The Lancet*, April 16, 1977.
20. ZAPP, J. J., "Gabapentin for the treatment of tinnitus: A case report." *ENT-Ear, Nose & Throat Journal*, February 2001, pgs. 114-116.
21. KUZNIECKY, R., S. HO, ET AL., "Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults." *Neurology*, February 2002, pgs. 368-372, AAN Enterprises, Inc.

22. PETROFF, O. A., F. HYDER, ET AL., "Effects of Gabapentin on Brain GABA, Homocarnosine, and Pyrrolidinone in Epilepsy Patients." *Epilepsia*, 2000, pgs. 675-680, Lippincott Williams & Wilkins, Inc., Baltimore.
23. WESTERBERG, B. D., J. B. ROBERSON, ET AL., "A double-blind placebo-controlled trial of baclofen in the treatment of tinnitus." *The American Journal of Otology*, 1996, pgs. 896-903, The American Journal of Otology, Inc.
24. COFFEY, R. J., D. CAHILL, ET AL., "Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study." *J Neurosurg*, February 1993, pgs. 226-232, vol. 78.
25. MEYTHALER, J. M., S. GUIN-RENFROE, ET AL., "CONTINUOUSLY INFUSED INTRATHECAL BACLOFEN FOR SPASTIC/DYSTONIC HEMIPLEGIA." *American Journal of Physical Medicine & Rehabilitation*, 1999, pgs. 155-161, no. 9, Lippincott Williams & Wilkins, Inc.
26. PENN, R. D., S. M. SAVOY, ET AL., "INTRATHECAL BACLOFEN FOR SEVERE SPINAL SPASTICITY." *New England Journal of Medicine*, June 8, 1989, pgs. 1571-1521, vol. 320.
27. KNUTSSON, E., U. LINDBLOM, ET AL., "Plasma and Cerebrospinal Fluid Levels of Baclofen (Lioresal®) at Optimal Therapeutic Responses in Spastic Paresis." *Journal of the neurological Sciences*, 1974, pgs. 473-484, vol. 23, Elsevier Scientific Publishing Company, Netherlands.
28. KROIN, J. S., "Intrathecal Drug Administration." *Clin. Pharmacokinet.* 1992, pgs. 319-326, vol. 22 (5), Adis International Limited.
29. KROIN, J. S. and R.D. PENN, "Cerebrospinal fluid pharmacokinetics of lumbar intrathecal baclofen", 1991, pgs. 67-77, Parthenon Publishing.
30. MULLER, H., J. ZIERSKI, ET AL. "Pharmacokinetics of Intrathecal Baclofen." 1998, pgs. 223-226, Springer-Verlag.
31. MILBRANDT, JC, ET AL., "GAD levels and muscimol binding in rat inferior colliculus following acoustic trauma." *Hearing Research*, 2000, pgs. 251-260, vol. 147 (1-2), Elsevier Science B.V.
32. CASPARY, D.M., T.M. HOLDER, ET AL. "AGE-RELATED CHANGES IN GABA_A RECEPTOR SUBUNIT COMPOSITION AND FUNCTION IN RAT AUDITORY SYSTEM." *Neuroscience*, 1999, pgs. 307-312, vol. 93, Elsevier Science, Ltd.

33. MILBRANDT JC, HUNTER C, ET AL., "Alterations of GABA_A Receptor Subunit mRNA Levels in the Aging Fischer 344 Rat Inferior Colliculus." The Journal of Comparative Neurology, 1997, pgs 455-65, vol. 379, Wiley-Liss, Inc.
34. MILBRANDT JC, ET AL., "GABA_A RECEPTOR BINDING IN THE AGING RAT INFERIOR COLLICULUS." Neuroscience, 1996, pgs. 449-458, vol. 73, no. 2, Elsevier Science Ltd., Great Britain.
35. SIMPSON, J.J. ET AL. "Recent advances in the pharmacological treatment of tinnitus." Trends in Pharmacology Sciences, January 1999, vol. 20.
36. JASTREBOFF, P., ET AL., "Neurophysiological approach to tinnitus patients." The American Journal of Otology, 1996, pgs. 236-240, vol. 17, The American Journal of Otology, Inc.
37. MERCHANT, S.N. ET AL., "Vestibular effects of intravenous lidocaine used in the treatment of tinnitus." The Journal of Laryngology and Otology, November 1986, pgs. 1249-1253, vol. 100.
38. PODOSHIN, L., M. ET AL., "Treatment of tinnitus by intratympanic installation of lignocaine (lidocaine) 2 per cent through ventilation tubes." The Journal of Laryngology and Otology, July 1992, pgs. 603-606, vol. 106.
39. RAZA, A., ET AL., "Age-related changes in brainstem auditory neurotransmitters: measures of GABA and acetylcholine function." Hearing Research, 1994, pgs. 221-230, vol. 77, Elsevier Science B.V.
40. KALTENBACH, J. A. "Neurophysiologic Mechanisms of Tinnitus." Journal of the American Academy of Audiology, March 2000, pgs. 125-137, vol. 11, no. 3.

Respectfully submitted,

BANNER & WITCOFF, LTD

Date: 9/18/03

By: William J. Allen
William J. Allen
Reg. No. 31,393

BANNER & WITCOFF, LTD.
10 South Wacker Drive
Suite 3000
Chicago, Illinois 60606
Telephone: (312) 463-5000
Facsimile: (312) 463-5001



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/611,459
		Filing Date	July 1, 2003
		First Named Inventor	Keith Robert Hildebrand
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 1 of 1	Attorney Docket Number	11738.00161	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-5,496,369	03-05-1996	Howard, III	
		US- 5,676,655	10-14-1997	Howard, III et al.	
		US- 5,713,847	02-03-1998	Howard, III et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail No. EV305251043US
Date of Deposit: September 18, 2003

I hereby certify that the attached correspondence, identified below, is being deposited with the United States Postal Service as "Express Mail Post Office Address" under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: Xiao A

In the Application of Keith Robert Hildebrand


Serial No.: 10/611,459

Filing Date: July 1, 2003

Title: A method for treating severe tinnitus

- ☐ Transmittal Form PTO/SB/21 (1 page)
- ☐ Information Disclosure Statement (5 pages)
- ☐ Form PTO/SB/08A (3 pages)
- ☐ References
- ☐ Return receipt postcard

Attorney Docket No.: 11738.00161



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/611,459
Filing Date	July 1, 2003
First Named Inventor	Keith Robert Hildebrand
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	11738.00161

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LEWIS, J.E., S.D.G. STEPHENS, ET AL., "Tinnitus and suicide." July 7, 1993, pgs. 50-54, vol. 19, Clin Otolaryngol.	
		MCFADDEN, D., Tinnitus: Facts, Theories, and Treatments, 1982, pgs. 1-9, National Academy Press, Washington D.C.	
		SATALOFF, J., R.T. SATALOFF, ET AL., "Tinnitus and vertigo in healthy senior citizens without a history of noise exposure." March 1987, pgs. 87-89, vol. 2, Thieme Medical Publishers, Inc., New York, NY	
		AXELSSON, A. and A. RINGDAHL, "Tinnitus-a study of its prevalence and characteristics.", 1989, pgs. 53-56, vol. 23, British Journal of Audiology	
		COLES, R. R. A., THOMPSON, ET AL., "Intra-tympanic injections in the treatment of tinnitus.", 1992, pgs. 240-242, vol. 17, Clin Otolaryngol.	
		DOBIE, R.A., "A review of randomized clinical trials in tinnitus.", The Laryngoscope, August 1999, pgs. 1202-1211, Lippincott Williams & Wilkins, Inc., Philadelphia.	
		LOCKWOOD, A.H., R.J. SALVI, ET AL., "The functional neuroanatomy of tinnitus: Evidence for limbic system links and neural plasticity.", January, 1998, Neurology, pgs. 114-120, vol. 50, American Academy of Neurology.	
		MOLLER, A.R., "Symptoms and signs caused by neural plasticity." Neurological Research, September, 2001, pgs. 565-572, vol. 23, Forefront Publishing Group.	
		DEN HARTIGH, J., C. G. J. M. HILDERS, ET AL., "Tinnitus suppression by intravenous lidocaine in relation to its plasma concentration." Clinical Pharmacology & Therapeutics, October 1993, pgs 415-420, vol. 54 no. 4, Mosby-Year Book, Inc.	
		OCHI, K. and J.J. EGGERMONT, "Effects of salicylate on neural activity in cat primary auditory cortex." Hearing Research, 1996, pgs 63-76, vol. 95, Elsevier Science B.V.	
		CASPARY, D.M., J. C. MILBRANDT, ET AL., "Central Auditory Aging: GABA Changes in the Inferior Colliculus." Experimental Gerontology, 1995, pgs. 349-360, vol. 30 nos. 3/4, Elsevier Science Ltd., USA.	
		MCGEER, E. G. and P. L. MCGEER, "AGE CHANGES IN THE HUMAN FOR SOME ENZYMES ASSOCIATED WITH METABOLISM OF THE CATECHOLAMINES, GABA AND ACETYLCHOLINE." Neurobiology of Aging, 1975, pgs. 287-305, Plenum Press, New York.	
		RAZA, A., J. C. MILBRANDT, ET AL., "Age-Related Changes in Brainstem Auditory Neurotransmitters: Measures of GABA and Acetylcholine Function." Hearing Research, 1994, pgs. 221-230, vol. 77, Elsevier Science B. V.	
		ARAKI, T., H. KATO, ET AL., "Selective changes of neurotransmitter receptors in middle-aged gerbil brain." Neurochem. Int., 1993, pgs. 541-548, vol. 23 no. 6, Pergamon Press Ltd.	
		MILBRANDT, J. C., R. L. ALBIN, ET AL., "Age-Related Decrease in GABA _A Receptor Binding in the Fischer 344 Rat Inferior Colliculus." Neurobiology of Aging, 1994, pgs. 699-703, vol. 15 no. 6, Elsevier Science Ltd., USA.	
		MOLLER, A. R., M. B. MOLLER, ET AL., "Some Forms of Tinnitus May Involve the Extralemniscal Auditory Pathway." Laryngoscope, October 1992, pgs. 1165-1171.	
		SZCZEPANIAK, W. S. and A. R. MOLLER, "EFFECTS OF L-BACLOFEN AND D-BACHLOFEN ON THE AUDITORY SYSTEM: A STUDY OF CLICK-EVOKED POTENTIALS FROM THE INFERIOR COLLICULUS IN THE RAT." Ann Otol Rhinol Laryngol, 1995, pgs. 399-404.	
		SZCZEPANIAK, W. S. and A.R. MOLLER, "Effects of (-) baclofen, clonazepam, and diazepam on tone exposure-induced hyperexcitability of the inferior colliculus in the rat: possible therapeutic implications for pharmacological management of tinnitus and hyperacusis." Hearing Research, 1996, pgs. 46-53, Elsevier Science B.V.	
		LEES, A. J., C. R. CLARKE, ET AL., "HALLUCINATIONS AFTER WITHDRAWAL OF BACLOFEN." The Lancet, April 16, 1977.	



	ZAPP, J. J., "Gabapentin for the treatment of tinnitus: A case report." ENT-Ear, Nose & Throat Journal, February 2001, pgs. 114-116.	
	KUZNIECKY, R., S. HO, ET AL., "Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults." Neurology, February 2002, pgs. 368-372, AAN Enterprises, Inc.	
	PETROFF, O. A., F. HYDER, ET AL., "Effects of Gabapentin on Brain GABA, Homocarnosine, and Pyrrolidinone in Epilepsy Patients." Epilepsia, 2000, pgs. 675-680, Lippincott Williams & Wilkins, Inc., Baltimore.	
	WESTERBERG, B. D., J. B. ROBERSON, ET AL., "A double-blind placebo-controlled trial of baclofen in the treatment of tinnitus." The American Journal of Otolaryngology, 1996, pgs. 896-903, The American Journal of Otolaryngology, Inc.	
	COFFEY, R. J., D. CAHILL, ET AL., "Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study." J Neurosurg, February 1993, pgs. 226-232, vol. 78.	
	MEYTHALER, J. M., S. GUIN-RENFROE, ET AL., "CONTINUOUSLY INFUSED INTRATHECAL BACLOFEN FOR SPASTIC/DYSTONIC HEMIPLEGIA." American Journal of Physical Medicine & Rehabilitation, 1999, pgs. 155-161, no. 9, Lippincott Williams & Wilkins, Inc.	
	PENN, R. D., S. M. SAVOY, ET AL., "INTRATHECAL BACLOFEN FOR SEVERE SPINAL SPASTICITY." New England Journal of Medicine, June 8, 1989, pgs. 1571-1521, vol. 320.	
	KNUTSSON, E., U. LINDBLOM, ET AL., "Plasma and Cerebrospinal Fluid Levels of Baclofen (Lioresal®) at Optimal Therapeutic Responses in Spastic Paresis." Journal of the neurological Sciences, 1974, pgs. 473-484, vol. 23, Elsevier Scientific Publishing Company, Netherlands.	
	KROIN, J. S., "Intrathecal Drug Administration." Clin. Pharmacokinet. 1992, pgs. 319-326, vol. 22 (5), Adis International Limited.	
	KROIN, J. S. and R.D. PENN, "Cerebrospinal fluid pharmacokinetics of lumbar intrathecal baclofen", 1991, pgs. 67-77, Parthenon Publishing.	
	MULLER, H., J. ZIERSKI, ET AL. "Pharmacokinetics of Intrathecal Baclofen." 1998, pgs. 223-226, Springer-Verlag.	
	MILBRANDT, JC, ET AL., "GAD levels and muscimol binding in rat inferior colliculus following acoustic trauma." Hearing Research, 2000, pgs. 251-260, vol. 147 (1-2), Elsevier Science B.V.	
	CASPARY, D.M., T.M. HOLDER, ET AL. "AGE-RELATED CHANGES IN GABA _A RECEPTOR SUBUNIT COMPOSITION AND FUNCTION IN RAT AUDITORY SYSTEM." Neuroscience, 1999, pgs. 307-312, vol. 93, Elsevier Science, Ltd.	
	MILBRANDT JC, HUNTER C, ET AL., "Alterations of GABA _A Receptor Subunit mRNA Levels in the Aging Fischer 344 Rat Inferior Colliculus." The Journal of Comparative Neurology, 1997, pgs 455-65, vol. 379, Wiley-Liss, Inc.	
	MILBRANDT JC, ET AL., "GABA _A RECEPTOR BINDING IN THE AGING RAT INFERIOR COLLICULUS." Neuroscience, 1996, pgs. 449-458, vol. 73, no. 2, Elsevier Science Ltd., Great Britain.	
	SIMPSON, J.J. ET AL. "Recent advances in the pharmacological treatment of tinnitus." Trends in Pharmacology Sciences, January 1999, vol. 20.	
	JASTREBOFF, P., ET AL., "Neurophysiological approach to tinnitus patients." The American Journal of Otolaryngology, 1996, pgs. 236-240, vol. 17, The American Journal of Otolaryngology, Inc.	
	MERCHANT, S.N. ET AL., "Vestibular effects of intravenous lidocaine used in the treatment of tinnitus." The Journal of Laryngology and Otolaryngology, November 1986, pgs. 1249-1253, vol. 100.	
	PODOSHIN, L., M. ET AL., "Treatment of tinnitus by intratympanic installation of lignocaine (lidocaine) 2 per cent through ventilation tubes." The Journal of Laryngology and Otolaryngology, July 1992, pgs. 603-606, vol. 106.	
	RAZA, A., ET AL., "Age-related changes in brainstem auditory neurotransmitters: measures of GABA and acetylcholine function." Hearing Research, 1994, pgs. 221-230, vol. 77, Elsevier Science B.V.	
	KALTENBACH, J. A. "Neurophysiologic Mechanisms of Tinnitus." Journal of the American Academy of Audiology, March 2000, pgs. 125-137, vol. 11, no. 3.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

